LBPMedicine(SH:688393) Sou Hu Cai Jing·2025-08-15 12:39Group 1 - The core viewpoint of the article highlights the financial performance and market position of Anbiping, a company in the medical device industry, which has a significantly high PE ratio compared to its peers [1][2] - As of August 15, Anbiping's closing stock price was 30.22 yuan, with a PE ratio of 1263.74 times, and a total market capitalization of 2.828 billion yuan [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, placing Anbiping at the 122nd position among its industry peers [1][2] Group 2 - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - The latest quarterly report for Q1 2025 shows that Anbiping achieved operating revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]